Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Sanofi builds diabetes portfolio

Posted 19 October 2020

Novo Nordisk faces its first rival of insulin aspart in Australia after the TGA green-lighted Sanofi's biosimilar Truvelog last week.

Truvelog marks Australia's first rapid-acting insulin biosimilar and rounds out Sanofi's insulin portfolio which includes rapid-acting insulin Apidra as well as long-acting insulins Optisulin and Toujeo

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
UPDATES: UNICEF stockpiling one billion syringes
Approvals Action
Shakeup for insulin
New biosim plus hypertension and herpes generics
Top of the Hill
Avoiding the Emperor's mistake
Not everyone is convinced about industry's budget win